| Name | TNIK-IN-3 |
| Description | TNIK-IN-3 is a highly potent and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK). It exhibits a strong selectivity for TNIK with an IC50 value of 0.026 μM. Additionally, TNIK-IN-3 demonstrates inhibitory activity against Flt4 (IC50 = 0.030 μM), Flt1 (IC50 = 0.191 μM), and DRAK1 (IC50 = 0.411 μM). This compound holds potential for carrying out research on colorectal cancer (CRC) [1]. |
| In vitro | TNIK-IN-3 (compound 21k) exhibits inhibitory activity against Aurora-A, GCK, and MLK3 with IC50 values of 0.517 μM, 3.657 μM, and 4.552 μM, respectively [1]. It reduces HCT116 and DLD-1 cell viability dose-dependently, with IC50s of 4.26 μM and 8.00 μM at 0.1 to 100 μM over three days [1]. The compound inhibits colony formation over 10 days (2.5 to 40 μM) and cell migration over 48 hours (5 to 20 μM) [1]. TNIK-IN-3 also dose-dependently decreases LRP5 and LRP6 protein expression, as well as the Wnt target genes AXIN2 and c-Myc in HCT116 cells (5 to 40 μM, 48 hours), and significantly reduces JNK1/2 phosphorylation in Hela cells (5 to 20 μM, 48 hours) [1]. |
| In vivo | TNIK-IN-3 (compound 21k), administered orally at dosages of 100-150 mg/kg twice daily for 18 days, dose-dependently reduces tumor growth in six-week-old female NOD-SCID mice injected with HCT116 cells[1]. The higher dose of 150 mg/kg resulted in significant tumor suppression without causing weight loss or any noticeable side effects. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (129.06 mM), Sonication is recommended.
|
| Keywords | βcatenin | Wnt/β-catenin | Wnt/betacatenin | Wnt/b-catenin | Wnt | TNIK-IN-3 | TNIKIN3 | TNIK IN 3 | TNIK | beta-catenin | betacatenin | bcatenin |
| Inhibitors Related | Chlorquinaldol | Echinacoside | Urea | Wnt pathway activator 1 | CHIR-99021 | XAV-939 | Monensin sodium salt | Isoquercetin | Fluocinolone (Acetonide) | KY-05009 | Methyl Vanillate | Bisdemethoxycurcumin |
| Related Compound Libraries | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Anti-Alzheimer's Disease Compound Library | Kinase Inhibitor Library | Neuroprotective Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | Wnt/Hedgehog/Notch Compound Library | Anti-Liver Cancer Compound Library | Anti-Cancer Active Compound Library | Neuronal Differentiation Compound Library |
United States
